The AMFm aims to enable countries to increase the provision of affordable ACTs through the public, private for-profit and not-for-profit sectors. This will save lives and reduce the use of less-effective treatments to which malaria parasites are becoming increasingly resistant. It will also reduce the use of artemisinin as a single treatment or monotherapy, thereby delaying the onset of resistance to that drug and preserving its effectiveness.
To achieve this aim, the Global Fund has negotiated lower ACT prices with manufacturers and will pay a large proportion of this (a ‘Co-Payment’) directly to manufacturers on behalf of buyers across the public, private for-profit and not-for-profit sectors.
Countries participating in AMFm must also implement “supporting interventions” to ensure the increased availability and safe use of ACTs. These interventions include public awareness campaigns, training and supportive supervision for ACT providers, policy and regulatory measures, pharmacovigilance planning and programs to improve access to ACTs among the poor and children. Countries may also implement additional supporting interventions to improve malaria case management, such as expanding the use of rapid diagnostic tests for malaria.
The first phase of AMFm will be rigorously assessed through an independent evaluation. The results of this evaluation will inform the Board’s decision to expand, modify or terminate the AMFm at the Global Fund.
Contact | Report Fraud and Abuse | Legal | RSS | Sitemap
© 2013 The Global Fund to Fight AIDS, Tuberculosis and Malaria